Tricuspid atresia medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
*The mainstay of therapy for the cyanotic neonate with severe[[ pulmonary stenosis]] and small-sized [[VSD]] is using[[ prostaglandin E1]] (PGE1) for keeping patency of [[ductus arteriosis]]. | *The mainstay of therapy for the cyanotic neonate with severe[[ pulmonary stenosis]] and small-sized [[VSD]] is using[[ prostaglandin E1]] (PGE1) for keeping patency of [[ductus arteriosis]].<ref name="AkkinapallyHundalani2018">{{cite journal|last1=Akkinapally|first1=Smita|last2=Hundalani|first2=Shilpa G|last3=Kulkarni|first3=Madhulika|last4=Fernandes|first4=Caraciolo J|last5=Cabrera|first5=Antonio G|last6=Shivanna|first6=Binoy|last7=Pammi|first7=Mohan|title=Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions|journal=Cochrane Database of Systematic Reviews|year=2018|issn=14651858|doi=10.1002/14651858.CD011417.pub2}}</ref> | ||
*The mainstay of therapy for [[heart failure]] symptoms is using [[diuretic]] for reduction of [[congestion]] and then starting [[ ACEI]]. | *The mainstay of therapy for [[heart failure]] symptoms is using [[diuretic]] for reduction of [[congestion]] and then starting [[ ACEI]]. | ||
Revision as of 07:08, 28 August 2020
|
Tricuspid atresia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenarios |
|
Case Studies |
|
Tricuspid atresia medical therapy On the Web |
|
American Roentgen Ray Society Images of Tricuspid atresia medical therapy |
|
Risk calculators and risk factors for Tricuspid atresia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2]Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Medical Therapy
- The mainstay of therapy for the cyanotic neonate with severepulmonary stenosis and small-sized VSD is usingprostaglandin E1 (PGE1) for keeping patency of ductus arteriosis.[1]
- The mainstay of therapy for heart failure symptoms is using diuretic for reduction of congestion and then starting ACEI.
References
- ↑ Akkinapally, Smita; Hundalani, Shilpa G; Kulkarni, Madhulika; Fernandes, Caraciolo J; Cabrera, Antonio G; Shivanna, Binoy; Pammi, Mohan (2018). "Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD011417.pub2. ISSN 1465-1858.